HCW Biologics (HCWB) Registration filing summary

Offering details and pricing

• Registration statement covers resale of 427,046 shares of common stock issued on May 22, 2026, plus up to 2,419,929 shares issuable upon exercise of pre-funded warrants and up to 2,846,975 shares issuable upon exercise of common stock purchase warrants, all related to a May 21, 2026 Securities Purchase Agreement.

• Shares and warrants are being registered for resale by selling stockholders, not as a primary offering.

• Shares and warrant shares are fully paid, nonassessable, and validly issued upon exercise and payment of applicable exercise prices.

Management team and governance

• Registration statement signed by CEO Hing C. Wong, CFO Rebecca Byam, Chairman Scott T. Garrett, and directors Rick S. Greene and Lisa M. Giles.

• Multiple management contracts and employment agreements are referenced, including with CEO Hing C. Wong and other executives.

Risk factors and disclosures

• Certain information in exhibits has been excluded as immaterial and confidential, with the company agreeing to furnish such information to the SEC upon request.